文献速递胸部肿瘤放疗放疗物理与技术

冠状动脉钙化与III期肺癌放疗后心脏风险

Coronary Artery Calcifications and Cardiac Risk After Radiation Therapy for Stage III Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-08-19

研究分析109例接受中位74 Gy放疗的III期非小细胞肺癌患者,冠脉钙化与心脏事件累积发生率相关。冠脉钙化阳性者心脏事件风险显著高于无钙化者,冠脉钙化可作为识别高危患者的心脏风险因素。

要点

  • 冠脉钙化阳性患者心脏事件风险显著高于无钙化者。
  • 钙化负担与心脏毒性在单因素和多因素分析中均相关。
  • 冠脉钙化可帮助筛选需转诊的高危患者。

核心结论

  • 冠脉钙化是心脏风险因素,可识别高危患者以供医疗转诊并指导临床决策。

研究设计与样本

  • 分析前瞻性剂量递增试验中接受中位74 Gy放疗的III期非小细胞肺癌患者,评估心脏事件累积发生率。

主要发现

  • 109例患者中26例在中位26个月(范围1-84个月)后发生心脏事件。
  • 模拟CT上64例(59%)有冠脉钙化,中位体积0.2 cm3(范围0.01-8.3)。
  • 无、低、高钙化组心脏事件发生率分别为7%(3/45)、29%(9/31)、42%(14/33)。

关键数值与推荐

  • 钙化定义基于模拟CT(130 HU阈值)勾画,分无、低、高,以中位体积划分低和高。
  • 心脏事件定义为症状性积液、心包炎、不稳定心绞痛、梗死、显著心律失常和/或心力衰竭。
  • 4年竞争风险调整后事件率:无钙化4%、低钙化23%、高钙化34%。

临床怎么用

  • 利用模拟CT评估冠脉钙化,识别心脏毒性高危患者。
  • 对冠脉钙化阳性患者考虑医疗转诊和心脏风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Heart dose and heart disease increase the risk for cardiac toxicity associated with radiation therapy. We hypothesized that computed tomography (CT) coronary calcifications are associated with cardiac toxicity and may help ascertain baseline heart disease. METHODS AND MATERIALS: We analyzed the cumulative incidence of cardiac events in patients with stage III non-small cell lung cancer receiving median 74 Gy on prospective dose-escalation trials. Events were defined as symptomatic effusion, pericarditis, unstable angina, infarction, significant arrhythmia, and/or heart failure. Coronary calcifications were delineated on simulation CTs using radiation software program (130 HU threshold). Calcifications were defined as "none," "low," and "high," with median volume dividing low and high. RESULTS: Of 109 patients, 26 had cardiac events at median 26 months (range, 1-84 months) after radiation therapy. Median follow-up in surviving patients was 8.8 years (range, 2.3-17.3). On simulation CTs, 64 patients (59%) had coronary calcifications with median volume 0.2 cm3 (range, 0.01-8.3). Only 16 patients (15%) had baseline coronary artery disease. Cardiac events occurred in 7% (3 of 45), 29% (9 of 31), and 42% (14 of 33) of patients with no, low, and high calcifications, respectively. Calcification burden was associated with cardiac toxicity on univariate (low vs none: hazard ratio [HR] 5.0, P = .015; high vs none: HR 8.1, P < .001) and multivariate analyses (low vs none: HR 7.0, P = .005, high vs none: HR 10.6, P < .001, heart mean dose: HR 1.1/Gy, P < .001). Four-year competing risk-adjusted event rates for no, low, and high calcifications were 4%, 23%, and 34%, respectively. CONCLUSIONS: The presence of coronary calcifications is a cardiac risk factor that can identify high-risk patients for medical referral and help guide clinicians before potentially cardiotoxic cancer treatments.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Wang K, Malkin HE, Patchett ND, et al. Coronary Artery Calcifications and Cardiac Risk After Radiation Therapy for Stage III Lung Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 34419565. doi:10.1016/j.ijrobp.2021.08.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。